Locum Consultant in Medical Oncology

The appointee will be based at The Christie and will provide consultant level care for patients with HPB and NET malignancies. This includes providing outpatient review through the outpatient clinics and day case units (as appropriate), where Systemic Anti-Cancer Therapy Treatments are delivered, as well as inpatient care on the main adult oncology wards.
There are four consultants currently working in the HPB (composed of primary liver cancer (hepatocellular carcinoma), pancreas cancer, biliary tract cancers (cholangiocarcinoma and gallbladder cancer) and NET disease group; Dr Richard Hubner, Dr Mairéad McNamara, Dr Victoria Foy and Dr Melissa Frizziero.
Approximately 500 new patients are seen each year (80% with advanced/metastatic disease), and approximately 23% of all these patients are entered in to clinical trials. In addition. The Christie has an international reputation in the treatment of NET (accredited as a Centre of Excellence by the European NET Society (ENETS) initially in 2011. The HPB/NET disease group is supported by clinical research fellows, a specialist registrar, research nurses, clinical nurse specialists, nurse clinicians, general practitioners with a specialist interest in oncology and clinical trials co-ordinators.
The post holder will be expected to maintain existing research and trial activity within the disease groups, working with colleagues from Research and Innovation.
**The role will be responsible for**:

- Management of patients with HPB and NET malignancies receiving standard therapy and in phase I/II/III trials, including treatment decisions and ongoing care.
- Participating in all relevant aspects of clinical governance, including maintaining up to date protocols, guidelines and clinical audit, under the supervision of the other consultants in the unit.
- Contribute to current research projects and establish new opportunities to expand and develop research within the disease groups.
- Revision and development of evidence-based protocols for patients and undertaking the administrative duties associated with the care of their patients.
- Maintaining a level of continuing professional development, consistent with the recommendations of the Royal College of Physicians.
- Contributing to the undergraduate teaching of medical students on oncology topics, as appropriate.
- Actively contributing to the training of junior doctors and other multi-disciplinary team members in both in-patient and outpatient departments, as appropriate, including acting as clinical/educational supervisor.
- Undertake clinical audit as a member of The Christie Medical Staff Committee.

The Christie is one of Europe’s leading cancer centres, treating over 60,000 patients a year. We are based in Manchester and serve a population of 3.2 million across Greater Manchester & Cheshire, but as a national specialist around 15% patients are referred to us from other parts of the country.
We provide radiotherapy through one of the largest radiotherapy departments in the world; chemotherapy on site and through 14 other hospitals; highly specialist surgery for complex and rare cancer; and a wide range of support and diagnostic services. We are also an international leader in research, with world first breakthroughs for over 100 years.
We run one of the largest early clinical trial units in Europe with over 300 trials every year. Cancer research in Manchester, most of which is undertaken on the Christie site, has been officially ranked the best in the UK.
This post is for 10 Programmed Activities (PAs) per week to support the clinical service within Hepato-pancreatico-biliary (HPB) and neuroendocrine tumour (NET) disease group. This is a 6-month fixed term post, with potential for a further 6 month extension.
Role Purpose
The appointee will be based at The Christie and will provide consultant level care for patients with HPB and NET malignancies. This includes providing outpatient review through the outpatient clinics and day case units (as appropriate), where Systemic Anti-Cancer Therapy Treatments are delivered, as well as inpatient care on the main adult oncology wards. The inpatient workload is supported by Consultant Acute Physicians who work in the Oncology Assessment Unit and the consultant providing Acute Oncology input to the Oncology base wards.
There are four consultants currently working in the HPB (composed of primary liver cancer (hepatocellular carcinoma), pancreas cancer, biliary tract cancers (cholangiocarcinoma and gallbladder cancer) and NET disease group; Dr Richard Hubner, Dr Mairéad McNamara, Dr Victoria Foy and Dr Melissa Frizziero. The group has a very active clinical research programme (predominantly phase II/III), with close links to basic research laboratories in the Cancer Research UK Manchester Institute.
Approximately 500 new patients are seen each year (80% with advanced/metastatic disease), and approximately 23% of all these patients are entered in to clinical trials. In addition, Th